Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26916440)

Published in Bioorg Med Chem Lett on February 16, 2016

Authors

Maria Elena Meza-Aviña1, Mary A Lingerfelt1, Linda M Console-Bram2, Thomas F Gamage2, Haleli Sharir2, Kristen E Gettys1, Dow P Hurst1, Evangelia Kotsikorou3, Derek M Shore1, Marc G Caron4, Narasinga Rao1, Larry S Barak4, Mary E Abood2, Patricia H Reggio1, Mitchell P Croatt1

Author Affiliations

1: Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States.
2: Center for Substance Abuse Research, Temple University, Philadelphia, Pennsylvania 19140, United States.
3: Department of Chemistry, University of Texas - Pan American, Edinburg, Texas 78539, United States.
4: Duke University Medical Center, Durham, North Carolina 27709, United States.

Articles cited by this

Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63

Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60

The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain (2008) 1.54

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene (2010) 1.36

The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene (2010) 1.32

Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24

A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol (2010) 1.21

Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol (2011) 1.17

Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther (2011) 1.03

The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene (2012) 1.00

Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2013) 0.88

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. J Med Chem (2009) 0.83

Design, synthesis, and 3D-QSAR analysis of novel 1,3,4-oxadiazol-2(3H)-ones as protoporphyrinogen oxidase inhibitors. J Agric Food Chem (2010) 0.80